BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Beijing InnoCare Pharma Tech Co. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Beijing InnoCare Pharma Tech Co.'
 s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06775860-1392@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:Soficitinib (ICP-332): Phase 3 readout est. (NCT06775860)
DESCRIPTION:Soficitinib (ICP-332)\, phase 3\, Atopic Dermatitis.\nStudy: IC
 P-332 in Subjects With Moderate to Severe Atopic Dermatitis\nEstimated pri
 mary completion: 25 November 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/soficitinib-icp-332#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06775860
URL:https://assetmemo.bio/drug/soficitinib-icp-332#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07236099-1392@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Soficitinib (ICP-332): Phase 2 readout est. (NCT07236099)
DESCRIPTION:Soficitinib (ICP-332)\, phase 2.\nStudy: Study of the Efficacy 
 and Safety of ICP-332 in Participants With Prurigo Nodularis\nEstimated pr
 imary completion: March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/soficitinib-icp-332#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07236099
URL:https://assetmemo.bio/drug/soficitinib-icp-332#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07440537-1808@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Fadeucravacitinib: Phase 2 readout est. (NCT07440537)
DESCRIPTION:Fadeucravacitinib\, phase 2.\nStudy: Evaluate the Efficacy and 
 Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Dou
 ble-blind Study\nEstimated primary completion: March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/fadeucravacitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07440537
URL:https://assetmemo.bio/drug/fadeucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465433-5647@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270829
DTEND;VALUE=DATE:20270830
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT06465433)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Extension Study to Provide Conti
 nued Treatment for Patients With Hematologic Malignancies Previously Enrol
 led in Studies With Tafasitamab\nEstimated primary completion: 29 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06465433
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104565-5647@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270923
DTEND;VALUE=DATE:20270924
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07104565)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Study to Assess the Safety and T
 olerability of Tafasitamab in Adult Participants With Primary Autoimmune B
 lood Cell Disorders\nEstimated primary completion: 23 September 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07104565
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082686-2932@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Mesutoclax: Phase 2 readout est. (NCT07082686)
DESCRIPTION:Mesutoclax\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Study to
  Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or 
 Refractory Mantle Cell Lymphoma (APEX-06)\nEstimated primary completion: D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mesutoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07082686
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06845241-3427@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:ICP-490: Phase 1/2 readout est. (NCT06845241)
DESCRIPTION:ICP-490\, phase 1/2.\nStudy: Evaluate the Safety\, Tolerability
 \, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hod
 gkin Lymphoma\nEstimated primary completion: July 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/icp-490#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06845241
URL:https://assetmemo.bio/drug/icp-490#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07378527-1392@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Soficitinib (ICP-332): Phase 2/3 readout est. (NCT07378527)
DESCRIPTION:Soficitinib (ICP-332)\, phase 2/3.\nStudy: Study of the Efficac
 y and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
 \nEstimated primary completion: September 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/soficitinib-icp-332#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07378527
URL:https://assetmemo.bio/drug/soficitinib-icp-332#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06521255-5647@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tafasitamab: Phase 3 readout est. (NCT06521255)
DESCRIPTION:Tafasitamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combin
 ation With Gemcitabine and Oxaliplatin Versus Rituximab in Combination Wit
 h Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse
  Large B-Cell Lymphoma\nEstimated primary completion: September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06521255
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896590-2932@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Mesutoclax: Phase 3 readout est. (NCT07896590)
DESCRIPTION:Mesutoclax\, phase 3.\nStudy: Orelabrutinib Plus ICP 248 vs Ore
 labrutinib for Relapsed/Refractory Marginal Zone Lymphoma\nEstimated prima
 ry completion: October 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/mesutoclax#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07896590
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07727486-1808@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Fadeucravacitinib: Phase 2 readout est. (NCT07727486)
DESCRIPTION:Fadeucravacitinib\, phase 2.\nStudy: A Study to Evaluate the Ef
 ficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndr
 ome\nEstimated primary completion: December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/fadeucravacitinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07727486
URL:https://assetmemo.bio/drug/fadeucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047612-1392@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Soficitinib (ICP-332): Phase 2/3 readout est. (NCT07047612)
DESCRIPTION:Soficitinib (ICP-332)\, phase 2/3.\nStudy: ICP-332 in Subjects 
 With Non-segmental Vitiligo\nEstimated primary completion: April 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/soficitinib-icp-332#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07047612
URL:https://assetmemo.bio/drug/soficitinib-icp-332#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925190-2932@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Mesutoclax: Phase 3 readout est. (NCT07925190)
DESCRIPTION:Mesutoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Study 
 Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untr
 eated Acute Myeloid Leukemia (AML) Patients\nEstimated primary completion:
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mesut
 oclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07925190
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06378138-2932@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301125
DTEND;VALUE=DATE:20301126
SUMMARY:Mesutoclax: Phase 2/3 readout est. (NCT06378138)
DESCRIPTION:Mesutoclax\, phase 2/3\, Chronic Lymphocytic Leukemia.\nStudy: 
 ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymp
 hocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)\nEstimated primary c
 ompletion: 25 November 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/mesutoclax#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06378138
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784101-2932@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20321031
DTEND;VALUE=DATE:20321101
SUMMARY:Mesutoclax: Phase 3 readout est. (NCT07784101)
DESCRIPTION:Mesutoclax\, phase 3\, Mantle Cell Lymphoma.\nStudy: A Phase 3 
 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib
  Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle C
 ell Lymphoma (r/r MCL).\nEstimated primary completion: October 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/mesutoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07784101
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
